Nanosilver is not a 'silver bullet' in long-term treatment of infections

Nanosilver is not a 'silver bullet' in long-term treatment of infections
Graphical abstract. Credit: DOI: 10.1186/s12951-021-01027-8

New research from the University of Technology Sydney (UTS) has found that pathogens that form biofilms can evolve to survive nanosilver treatment. The study is the first to demonstrate that long-term nanosilver treatment can increase the risk of recurrent infections.

The research is published in the Journal of Nanobiotechnology.

Nanosilver is a potent antimicrobial that is currently used in medical devices such as internal catheters, as well as wound dressings, in particular for burn wounds, to fight or prevent infections. It is also one of the most commercialized antimicrobial nanoparticles, and has been incorporated into from , such as soaps and toothpaste, to washing machines and fridges, even children's products, such as in kids socks to prevent odor.

Researchers at UTS's iThree Institute studied adaptation phenomena in the bacterium Pseudomonas aeruginosa, in its biofilm form of growth, and observed a novel adaptation mechanism not seen in previous planktonic growth studies. Following prolonged treatment, nanosilver killed 99.99% of the bacterial population with only 0.01% cells surviving for longer. This minute fraction of 'persisters' resumed normal growth upon discontinuation of the nanoparticle treatment.

"Understanding how pathogens develop adaptation mechanisms to nanoparticles is key in our effort to overcome the phenomena, including in biofilms as the major form of growth of pathogenic bacteria. This is to protect the efficacy of important alternative antimicrobials, like nanosilver, in this era of increasing ," said lead author Dr. Cindy Gunawan.

The study first author, Dr. Riti Mann, said the research findings will also help develop strategies on the better management of nanoparticle use as antimicrobials, in particular those that involving long-term exposures.

"Based on this study, we recommend monitoring patients not only during, but also after prolonged use of nanoparticle treatment for safeguarding against recurrent infections.

"The that bacteria can adapt to nanoparticles means we need effective regulation of the use of , with clear risks versus benefits assessment and clear antimicrobial targets. With limited development of new effective antibiotics over the past decades, we need to preserve the efficacy of the alternative antimicrobials to fight untreatable infections, saving lives and billions of dollars in healthcare," said Dr. Gunawan.

The bacterium used in the study, Pseudomonas aeruginosa, often attach themselves on catheter surfaces, as well as to wounds and lung linings, growing biofilms, which can be difficult to control.

More information: Riti Mann et al, Evolution of biofilm-forming pathogenic bacteria in the presence of nanoparticles and antibiotic: adaptation phenomena and cross-resistance, Journal of Nanobiotechnology (2021). DOI: 10.1186/s12951-021-01027-8

Citation: Nanosilver is not a 'silver bullet' in long-term treatment of infections (2021, October 11) retrieved 19 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Rampant use of antibacterial nanosilver is a resistance risk


Feedback to editors